BOSTON, Oct. 26 /PRNewswire/ -- Scimitar Equity Research, Inc. (Scimitar) issues a review of StatSure Diagnostic Systems, Inc. (OTC Bulletin Board: SSUR), entitled, "Opportunity Unfolds for Investors Seeking to Participate In a Proprietary Point-of-Care Firm".
This review is available at our website: http://www.scimitarequity.com.
StatSure Diagnostic Systems, Inc. is engaged in the development, manufacture and marketing of rapid immunoassay tests for the detection of sexually transmitted and other infectious diseases; in addition, the Company has developed and is marketing a product line of patented, oral- fluid collection devices. The Company's proprietary platforms provide significant customer benefits and competitive advantages as compared to similar products that are currently available. Improved accuracy, operator convenience, and reduced risk of infection from collecting and handling specimens, have been engineered into SDS products. All of the company's diagnostic tests are based on the same easy-to-use technology platform, thus facilitating the development of future products. Certain of these products are sold in the United States as well as internationally to various distributors for use in clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations. Please visit our website at http://www.StatSure.com
ABOUT Scimitar Equity Research, Inc.
Scimitar Equity Research, Inc. provides sponsored equity research of the health sciences industry for the institutional and investment communities. We certify that all the views expressed in this review, accurately reflect our personal views about SSUR.OB (OTC Bulletin Board) and its or their securities. No part of our compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views contained in this review. Investors are advised that this analysis and review is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. Scimitar was paid for preparing this review. This analysis and review does not have regard to the specific investment objectives, financial situation and the information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Any opinions expressed are statements of our own judgment as of the date of publication and are subject to change without notice. Please read all our important disclosures.
Scimitar Equity Research, Inc.
Henry W. McCusker
Director of Research
phone: (617) 559.1080
fax: (617) 559.1083
|SOURCE Scimitar Equity Research, Inc.|
Copyright©2007 PR Newswire.
All rights reserved